Bruker (NASDAQ:BRKR) Price Target Lowered to $75.00 at Citigroup

Bruker (NASDAQ:BRKR) had its price objective trimmed by Citigroup from $80.00 to $75.00 in a report released on Wednesday, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

BRKR has been the subject of several other reports. The Goldman Sachs Group cut their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Barclays cut their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Wells Fargo & Company cut their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, TD Cowen decreased their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Stock Performance

Shares of BRKR opened at $59.34 on Wednesday. Bruker has a 1 year low of $54.55 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. The stock’s fifty day moving average price is $63.97 and its two-hundred day moving average price is $66.51. The firm has a market cap of $8.98 billion, a PE ratio of 24.47, a PEG ratio of 2.32 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.74 earnings per share. On average, equities research analysts forecast that Bruker will post 2.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. TD Asset Management Inc boosted its position in Bruker by 7.4% during the 1st quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company’s stock valued at $168,036,000 after buying an additional 123,984 shares during the period. Atria Investments Inc purchased a new position in Bruker during the 1st quarter valued at about $1,142,000. Point72 Asset Management L.P. bought a new position in Bruker during the 2nd quarter valued at approximately $36,472,000. Epoch Investment Partners Inc. lifted its holdings in Bruker by 15.2% in the 1st quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company’s stock worth $43,857,000 after buying an additional 61,429 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of Bruker by 1,694.4% in the 2nd quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock worth $12,936,000 after buying an additional 191,435 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.